| pegylated liposomal doxorubicin / Generic mfg. |
ChiCTR-IPR-17012144: A pilot randomized controlled trial for comparing CDA-II in Combination With DT-PDCE versus DT-PDCE Alone in Subjects with Relapsed or Refractory Multiple Myeloma |
|
|
| Recruiting | N/A | 50 | | Dexamethasone 40 mg / d, oral, 4 d; thalidomide 100-200 mg / d, D1-4; cisplatin 10 mg / m2, D1-4; Pegylated liposomal doxorubicin 40 mg / m2, D1; Cyclophosphamide 400mg / m2, D1-4; Etoposide 40mg / (m2d), D1-4; Uroacitides Injection 300ml / d, D1-D7. ;Dexamethasone 40 mg / d, oral, 4 d; thalidomide 100-200 mg / d, D1-4; cisplatin 10 mg / m2, D1-4; Pegylated liposomal doxorubicin 40 mg / m2, D1; Cyclophosphamide 400mg / m2, D1-4; Etoposide 40mg / (m2d), D1-4 | Henan Cancer Hospital; Henan Cancer hospital, Self-financing | Relapsed or Refractory Multiple Myeloma | | | | |
ChiCTR-IPR-17011503: A pilot randomized controlled trial evaluating pegylated liposomal doxorubicin (PLD) /cyclophosphamide (CTX) versus epirubicin/CTX as neoadjuvant therapy for operable breast cancer |
|
|
| Recruiting | N/A | 90 | | pegylated liposomal doxorubicin(PLD) 35 mg/m2 plus cyclophosphamide (CTX) 600 mg/m2, every 21 days for 4 cycles. ;epirubicin 90 mg/m2 plus cyclophosphamide (CTX) 600 mg/m2, every 21 days for 4 cycles. | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, sponsored by reserchers | Breast Cancer | | | | |
ChiCTR2100050294: Efficacy analysis of vitamin B6 in preventing hand-foot syndrome caused by pegylated liposomal doxorubicin in patients with multiple myeloma——a single-center, prospective clinical study |
|
|
| Recruiting | N/A | 126 | | eat pyridoxine ;no intervention | Department of Hematology, the First Affiliated Hospital of Sun Yat-sen University; The First Affiliated Hospital of Sun Yat-sen University, 5010 Clinical Research Project of Sun Yat-sen University (2017005) | multiple myeloma | | | | |
NCT04055753: Study to Assess TOPO2A as a Biomarker for Sensitivity to Doxorubicin/Doxil in Soft Tissue Sarcoma |
|
|
| Active, not recruiting | N/A | 24 | US | Doxil, Doxorubicin | Fox Chase Cancer Center | Soft Tissue Sarcoma | 06/21 | 10/24 | | |
ChiCTR2000034609: Efficacy and safety of albumin bound paclitaxel combined with pegylated liposome doxorubicin in the treatment of platinum resistant or refractory ovarian cancer: an open, single arm, phase II prospective study |
|
|
| Recruiting | N/A | 51 | | Efficacy and safety of albumin bound paclitaxel combined with pegylated liposome doxorubicin | Shaanxi Provincial Cancer Hospital; Shaanxi Provincial Cancer Hospital, CSPC OUYI PHARMACEUTICAL CO.，LTD. | ovarian cancer | | | | |
SCENIC, NCT06292286: Secondary Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer |
|
|
| Recruiting | N/A | 18 | RoW | Carboplatin or cisplatin, Paraplatin or Platinol, Paclitaxel, gemcitabine or liposomal doxorubicin with or without bevacizumab or biosimilar, Taxol, Gemzar, Caelyx, Bevacizumab or biosimilar, Avastin or mvasi, Cytoreductive surgery | The University of Hong Kong | Recurrent Ovarian Carcinoma | 12/25 | 07/26 | | |
ChiCTR2100051982: Clinical study of calcium dobesilate in preventing hand-foot syndrome caused by pegylated liposome doxorubicin |
|
|
| Not yet recruiting | N/A | 238 | | Calcium dobesilate capsules ;None | The Fourth Hospital of Hebei Medical University; The Fourth Hospital of Hebei Medical University, CSPC Ouyi Pharmaceutical Co. LTD | Breast cancer | | | | |
NCT05976932: Circulating Tumor DNA Monitoring in Platinum-resistant Ovarian Cancer |
|
|
| Not yet recruiting | N/A | 20 | NA | pegylated liposomal doxorubicin, PLD | Fudan University | Ovarian Cancer | 04/24 | 10/24 | | |
easy laugh, NCT05656079: To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical Study |
|
|
| Recruiting | N/A | 204 | RoW | Pegylated liposomal doxorubicin, duomeisu, Doxorubicin Hydrochloride Liposome Injection, Epirubicin, biaoroubixing, Cyclophosphamid, huanlinxianan, Trastuzumab, qutuozhudankang, Pertuzumab, patuozhudankang, Docetaxel, duoxitasai | Shanghai Pudong Hospital, CSPC Ouyi Pharmaceutical Co., Ltd. | Breast Cancer | 09/24 | 09/25 | | |
ChiCTR2100048957: The effectiveness of pegylated liposomal doxorubicin to platinum-resistance ovarian cancer patients and nanogram assay |
|
|
| Not yet recruiting | N/A | 68 | | adriamycin treatment | Obstetrics & Gynecology Hospital of Fudan University; Obstetrics & Gynecology Hospital of Fudan University, National Natural Science Foundation of China, Youth Science Foundation, 82002750 | ovarian cancer | | | | |
ChiCTR1900028438: A prospective, real-world clinical study for pegylated liposomal doxorubicin (PLD) versus epirubicin in the neoadjuvant treatment of HER-2 positive breast cancer |
|
|
| Not yet recruiting | N/A | 600 | | pegylated liposomal doxorubicin + cyclophosphamide sequential taxine + trastuzumab ± pertuzumab regimen ;epirubicin + cyclophosphamide sequential taxine + trastuzumab ± pertuzumab regimen | Sen Memorial Hospital, Sun Yat-Sen University; Sen Memorial Hospital, Sun Yat-Sen University, CSPC Ouyi Pharmaceutical Co., Ltd. | Breast Cancer | | | | |
ChiCTR2300070063: Clinical Study of Pegylated Liposomal Doxorubicinin and Sintilimab plus Anlotinib in Patients with Advanced Triple-Negative Breast Cancer |
|
|
| Not yet recruiting | N/A | 81 | | Pegylated liposomal doxorubicinin and Sintilimab plus Anlotinib | Tianjin Cancer Hospital Airport Hospital; Tianjin Cancer Hospital Airport Hospital, CSPC Ouyi Pharmaceutical Co., Ltd. | Advanced Triple-negative Breast Cancer | | | | |
